CoChat
Sign Up
Cited by 61Retinal Diseases and TreatmentsDiabetes Treatment and ManagementDrug-Induced Ocular Toxicity

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration

Open access
Shor, Reut, Mihalache, Andrew, Noori, Atefeh, Shor, Renana, Kohly, Radha P., Popovic, Marko M., Muni, Rajeev H.·2025·JAMA Ophthalmology
DOI 10.1001/jamaophthalmol.2025.1455
Open this paper in CoChat — free account

Abstract

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are extensively used in treating diabetes and obesity, yet little is known about the long-term ocular effects of systemic prolonged exposure. Objective To evaluate the risk of developing neovascular age-related macular degeneration (nAMD) associated with the use of GLP-1 RAs in patients with diabetes. Design, setting, and participants This population-based, retrospective cohort study was conducted from January 2020 to November 2023, with a follow-up period of 3 years. Data analysis was performed from August 2024 to October 2024. The investigators used comprehensive administrative health and demographic data from patients in Ontario, Canada, which were collected by the Institute for Clinical Evaluative Sciences in the context of a universal public health care system. Inclusion criteria were patients aged 66 years or older with a diagnosis of diabetes and a minimum follow-up period of 12 months following initial diabetes diagnosis. Patients with incomplete Ontario Health Insurance Plan or Ontario Drug Benefit data or patients exposed to GLP-1 RA for less than 6 months were excluded. Of 1 119 517 eligible patients, a 1:2 matched cohort of 139 002 patients was created, including 46 334 patients who were exposed to GLP-1 RAs and 92 668 unexposed matched patients. Systemic comorbidities that were associated with any kind of AMD and socioeconomic status were used to calculate propensity scores. Exposure GLP-1 RA use fo…

Overview

Integrity signals

Registry

Crossref · 10.1001/jamaophthalmol.2025.1455

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A recent large retrospective cohort study found that the use of GLP-1s among patients with diabetes was associated with a twofold higher risk of incident neovascular age-related macular degeneration development compared with similar patients with diabetes who did not receive a GLP-1.

    “a recent large retrospective cohort study found that the use of GLP-1s among patients with diabetes was associated with a twofold higher risk of incident neovascular age-related macular degeneration development compared with similar patients with diabetes who did not receive a GLP-1 [18].”

    From Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US (2025) · cites this paper as [18]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. Vyawahare, 2022, Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment., Cureus, 14, 10.7759/cureus.29583 · DOI
  2. Fleckenstein, 2019, [Dry age-related macular degeneration - epidemiology and classification]., Klin Monbl Augenheilkd, 236, 1068, 10.1055/a-0958-9621 · DOI
  3. Ruiz-Moreno, 2021, Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study., Int Ophthalmol, 41, 3427, 10.1007/s10792-021-01906-x · DOI · Paper page
  4. Lee, 2017, Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes., Ann Pediatr Endocrinol Metab, 22, 15, 10.6065/apem.2017.22.1.15 · DOI
  5. Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes., N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
  6. Austin, 2011, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies., Pharm Stat, 10, 150, 10.1002/pst.433 · DOI · Paper page
  7. VanderBeek, 2024, Separating supplement effects from the patients who use them., JAMA Ophthalmol, 142, 1121, 10.1001/jamaophthalmol.2024.4569 · DOI
  8. Chua, 2023, Associations between HbA1c across the normal range, diagnosed, and undiagnosed diabetes and retinal layer thickness in UK Biobank cohort., Transl Vis Sci Technol, 12, 25, 10.1167/tvst.12.2.25 · DOI
  9. Blitzer, 2021, Association of metformin use with age-related macular degeneration: a case-control study., JAMA Ophthalmol, 139, 302, 10.1001/jamaophthalmol.2020.6331 · DOI
  10. Aggarwal, 2024, Metformin use and age-related macular degeneration in patients without diabetes., JAMA Ophthalmol, 142, 53, 10.1001/jamaophthalmol.2023.5478 · DOI
  11. Hsu, 2024, Association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and macular degeneration in patients with diabetes: a nationwide population-based study in Taiwan., Acta Diabetol, 61, 1161, 10.1007/s00592-024-02303-3 · DOI
  12. Ebrahimi, 2024, The potential effects of newer groups of glucose lowering drugs on age-related macular degeneration., Eye (Lond), 38, 2649, 10.1038/s41433-024-03066-5 · DOI
  13. Fonseca, 2019, Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide., J Clin Endocrinol Metab, 104, 4078, 10.1210/jc.2018-02685 · DOI
  14. The Diabetes Control and Complications Trial Research Group, 1998, Early worsening of diabetic retinopathy in the Diabetes Control and Complications trial., Arch Ophthalmol, 116, 874, 10.1001/archopht.116.7.874 · DOI · Paper page
  15. Puklin, 1982, Influence of long-term insulin infusion pump treatment of type I diabetes on diabetic retinopathy., Ophthalmology, 89, 735, 10.1016/S0161-6420(82)34730-2 · DOI
  16. Pang, 2018, The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy., Peptides, 100, 123, 10.1016/j.peptides.2017.08.003 · DOI
  17. Kang, 2017, Effects of incretin-based therapies on diabetic microvascular complications., Endocrinol Metab (Seoul), 32, 316, 10.3803/EnM.2017.32.3.316 · DOI
  18. Fan, 2014, Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats., Exp Eye Res, 127, 104, 10.1016/j.exer.2014.05.004 · DOI
  19. Ioanna, 2018, Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration., Graefes Arch Clin Exp Ophthalmol, 256, 325, 10.1007/s00417-017-3846-z · DOI
  20. Bain, 2019, Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review., Diabetes Obes Metab, 21, 454, 10.1111/dom.13538 · DOI
  21. Ahmad, 2021, Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: analyses from the LYDIA trial., Diabetes Obes Metab, 23, 1409, 10.1111/dom.14343 · DOI · Paper page
  22. Liang, 2007, CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway., Biochem Biophys Res Commun, 359, 716, 10.1016/j.bbrc.2007.05.182 · DOI
  23. Zhang, 2017, CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells., Sci Rep, 7, 8289, 10.1038/s41598-017-08840-y · DOI
  24. Zhang, 2011, Hypoxia specific SDF-1 expression by retinal pigment epithelium initiates bone marrow-derived cells to participate in choroidal neovascularization in a laser-induced mouse model., Curr Eye Res, 36, 838, 10.3109/02713683.2011.593107 · DOI
  25. Locatelli, 2022, Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway., J Pathol, 256, 468, 10.1002/path.5862 · DOI
  26. Ishibashi, 2024, Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: a cohort study using the Japanese health insurance claims database., Diabetes Obes Metab, 26, 1510, 10.1111/dom.15454 · DOI
  27. Shurter, 2013, Euglycemic progression: worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities., Diabetes Res Clin Pract, 100, 362, 10.1016/j.diabres.2013.03.018 · DOI
  28. Dicembrini, 2017, Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials., Acta Diabetol, 54, 933, 10.1007/s00592-017-1031-9 · DOI
  29. Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes., Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5 · DOI · Paper page
  30. Ruia? S, Kaufman? EJ. Macular degeneration. StatPearls. Accessed September 20, 2024. https://www.ncbi.nlm.nih.gov/books/NBK560778/
  31. Hobbs? SD, Tripathy? K, Pierce? K. Wet age-related macular degeneration (AMD). StatPearls. Accessed September 20, 2024. https://www.ncbi.nlm.nih.gov/books/NBK572147/
  32. Regulatory decision summary for Ozempic. Drug and Health Products Portal, Government of Canada. Accessed October 10, 2024. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00317

Cited by

Sorted by citations

Metadata

Authors
Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H.
Affiliations
  • University of Toronto (CA)
  • University Health Network (CA)
  • St. Michael's Hospital (CA)
ORCID
Venue
JAMA Ophthalmology
Publisher
American Medical Association (AMA)
Published
2025-07-01
Volume
143
Issue
7
Pages
587
ISSN
2168-6165 (ISSN-L)
DOI
10.1001/jamaophthalmol.2025.1455
OpenAlex
W4411046438
Cited by
61
References
7
Citations by year
2026: 33 · 2025: 28
FWCI
51.47
Type
journal article
Language
en
Open access
Locations
  • JAMA Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
Keywords
GLP-1 receptor agonists, neovascular age-related macular degeneration, diabetes mellitus, ocular adverse effects, drug safety, older adults, propensity score matching, Ontario Health Insurance Plan, Ontario Drug Benefit, obesity treatment, long-term drug exposure, comorbidities, socioeconomic status, health insurance status
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Ontario, Retrospective Studies, Risk Factors, Incidence, Wet Macular Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review